Collegium Pharmaceutical (COLL) Expected to Post Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.68 per share and revenue of $199.6250 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. During the same quarter last year, the firm earned $1.49 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL opened at $36.29 on Thursday. Collegium Pharmaceutical has a 52 week low of $29.19 and a 52 week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $1.18 billion, a P/E ratio of 17.79 and a beta of 0.73. The stock’s fifty day moving average is $34.78 and its two-hundred day moving average is $37.64.

Institutional Trading of Collegium Pharmaceutical

Hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after buying an additional 18,160 shares during the period. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares in the last quarter. State Street Corp grew its position in shares of Collegium Pharmaceutical by 1.3% during the fourth quarter. State Street Corp now owns 1,310,641 shares of the specialty pharmaceutical company’s stock worth $60,683,000 after buying an additional 16,730 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the period.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of recent analyst reports. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.